

CAPÍTULO X

Bibliografía

1. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial SEH-LELHA. Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002. *Hipertensión*. 2002;19 Supl 3:1-74.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289:2560-72.
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens*. 2003;21:1011-53.
4. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). *Eur Heart J*. 2003;24:1601-10.
5. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, Conthe P, et al. Adaptación española de la Guía Europea de Prevención Cardiovascular. *Hipertensión*. 2004;21:403-17.
6. World Health Organization, International Society of Hypertension writing group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003;21:1983-92.
7. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. *BMJ*. 2004;328:634-40.
8. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation*. 2003;108:2154-69.
9. Hemmelgarn BR, Zarnke KB, Campbell N, Feldman RD, McKay DW, McAlister FA, et al, for the Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol*. 2004;20:31-40.
10. Khan NA, McAlister FA, Campbell NRC, Feldman RD, Rabkin S, Mahon J, et al, for the Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part II - Therapy. *Can J Cardiol*. 2004;20:41-54.
11. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004;43 Suppl 1:S1-290.
12. American Diabetes Association: Position statement. Hypertension management in adults with diabetes. *Diabetes Care*. 2004;27 Suppl 1:S65-7.
13. Marín R, Goicoechea MA, Gorostidi M. Guías SEN. Riñón y enfermedad cardiovascular. *Nefrología*. 2004; 24 Suppl 6:S1-235.
14. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*. 2003;362:759-66.
15. Fox KM; EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. 2003;362:782-8.
16. Pfeffer MA, McMurray JVV, Velázquez EJ, Rouleau JL, Køber L, Maggioni AP, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*. 2003;349:1893-906.
17. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al, for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA*. 2003;290:2805-16.
18. Staessen JA, Thijsq L, Fagard R, Celis H, Birkenhager WH, Bulpitt CJ, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. *J Hypertens*. 2004;22:847-57.
19. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*. 2004;363:2022-31.
20. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. *N Engl J Med*. 2004;351:2058-68.
21. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. *JAMA*. 2004;292:2217-25.
22. Ruggenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al; for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. *N Engl J Med*. 2004;351:1941-51.
23. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med*. 2004;351:1952-61.
24. Lubsen J, Wagener G, Kirwan B-A, Bouwer S, Poole-Wilson PA. Effect of long-acting nifedipine on mortality and

- cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. *J Hypertens.* 2005;23:641-8.
25. Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, de la Cruz-Troca JJ, et al. Hypertension magnitude and management in the elderly population of Spain. *J Hypertens.* 2002;20:2157-64.
 26. Banegas JR, Segura J, Ruilope LM, Luque M, García-Robles R, Campo C, et al. Blood pressure control and physician management of hipertensión in hospital hypertension units in Spain. *Hypertension.* 2004;43:1338-44.
 27. Llisterri JL, Rodríguez G, Alonso FJ, Lou S, División JA, Santos JA, et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2002. *Med Clin (Barc).* 2004;122:165-71.
 28. Coca Payeras A. Evolución del control de la hipertensión arterial en Atención Primaria en España. Resultados del estudio Controlpres 2003. *Hipertensión.* 2005;22:5-14.
 29. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA.* 2004;291:1071-80.
 30. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med.* 2004;350:1495-504.
 31. Alderman MH, Furberg CD, Kostis JB, Laragh JH, Psaty BM, Ruilope LM, et al. Hypertension guidelines: criteria that might make them more clinically useful. *Am J Hypertens.* 2002;15:917-23.
 32. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. *N Engl J Med.* 2004;351:2870-4.
 33. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet.* 2005;65:217-23.
 34. Hart PD, Bakris GL. Hypertension control rates: time for translation of guidelines into clinical practice. *Am J Med.* 2004;117:62-4.
 35. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. *Lancet.* 2005;365:434-41.
 36. Birkenhäger WH, Reid JL, editores. *Handbook of hypertension.* En: Bulpitt CJ, editor. Vol. 6. *Epidemiology of hypertension.* Amsterdam: Elsevier; 1985.
 37. Kannel WB. Update on hypertension as a cardiovascular risk factor. En: Mancia G, Chalmers J, Julius S, Saruta T, Weber M, Ferrari A, et al, editors. *Manual of Hypertension.* New York: Churchill Livingstone; 2002. p.3-19.
 38. Benetos A, Rudnicki A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. *Hypertension.* 1998;32:560-4.
 39. Pastor R, Banegas JR, Damián J, Appel LJ, Guallar E. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. *Ann Intern Med.* 2003;139:731-9.
 40. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Arch Intern Med.* 1997;157:2413-46.
 41. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. *J Hypertens.* 1999;17:151-83.
 42. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA.* 1991;265:3255-64.
 43. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet.* 1997;350:757-64.
 44. Banegas JR, Rodríguez Artalejo F, Cruz JJ, Guallar P, Rey J. Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. *Hypertension.* 1998;32:998-1002.
 45. Banegas JR, Rodríguez Artalejo F, Cruz JJ, de Andrés B, Rey J. Mortalidad relacionada con la presión arterial y la hipertensión en España. *Med Clin (Barc).* 1999;112:489-94.
 46. Banegas JR, Rodríguez Artalejo F. El problema de la hipertensión arterial en España. *Rev Clin Esp.* 2002;202:12-5.
 47. Aranda P, Villar J, editores. Grupo Colaborativo Andaluz sobre factores de riesgo vascular. Estudio epidemiológico andaluz sobre factores de riesgo vascular. Estudio Al Andaluz 1990. Sevilla: Consejería de Salud;1993.
 48. Puras A, Sanchis C, Artigao LM, Divison JA. Prevalence, awareness, treatment, and control of hypertension in a Spanish population. *Eur J Epidemiol.* 1998;14:31-6.
 49. Compañ L, Vioque J, Quiles J, Hernández-Aguado I, Borrás F. Prevalencia y control de la hipertensión arterial en la población adulta de la Comunidad Valenciana, 1994. *Med Clin (Barc).* 1998;110:328-33.
 50. Masiá R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. *J Epidemiol Community Health.* 1998;52:707-15.
 51. Sans S, Paluzie G, Balañá LL, Puig T, Balaguer-Vintró I. Tendencias de la prevalencia, conocimiento, tratamiento y control de la hipertensión arterial entre 1986 y 1996: estudio MONICA-Cataluña. *Med Clin (Barc).* 2001;117:246-53.
 52. Dalfó Baqué A, Escribà Jordana JM, Benítez Camps M, Vila Coll MA, Senar Abellan E, Tovillas Morán FJ, et al. Diagnóstico y seguimiento de la hipertensión arterial en Cataluña. Estudio DISEHTAC. *Aten Primaria.* 2001;28:305-10.
 53. Suárez C, Gabriel R. Epidemiología de la hipertensión arterial en España. *Cardiovasc Risk Factors.* 2000;9:239-46.
 54. González Juanatey JR, Alegría E, Lozano JV, Llisterri JL, García Acuña JM, González Maqueda I. Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999. *Rev Esp Cardiol.* 2001;54:139-49.
 55. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. *JAMA.* 2003;289:2363-9.
 56. De Pablos-Velasco P, Martínez-Martín FJ, Rodríguez F, Ruilope LM, García Robles R. Prevalence, awareness, treatment and control of hypertension in a Canarian population. Relationship with glucose tolerance categories. The Guía Study. *J Hypertens.* 2002;20:1965-71.
 57. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del estudio Controlpres 2001. *Hipertensión.* 2002;19:390-9.
 58. Coca A. Control de la hipertensión arterial en España. Resultados del estudio Controlpres 95. *Hipertensión.* 1995;12:182-8.
 59. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del Estudio Controlpres 98. *Hipertensión.* 1998;15:298-307.
 60. Pardell H, editor. *Hipertensión Arterial en España. 2.ª ed.* Madrid: Liga Española para la lucha contra la hipertensión arterial;1987.
 61. Roca-Cusachs A, Merino J, Aranda P, Gil V, Guayta R, Abellán J, et al. La observancia terapéutica en el paciente hipertenso. Madrid: Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial; 1996.
 62. Puigventós F, Llodrá V, Vilanova M, Delgado O, Lázaro M, Forteza-Rey J, et al. Cumplimiento terapéutico en el tratamiento de la hipertensión: 10 años de publicaciones en España. *Med Clin (Barc).* 1997;109:702-6.
 63. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. *Hypertension.* 2004;43:10-7.

64. Sans S, Kesteloot H, Kromhout D on behalf of the Task Force of the European Society of Cardiology on cardiovascular mortality and morbidity statistics in Europe. The burden of cardiovascular diseases mortality in Europe. *Eur Heart J*. 1997;18:1231-48.
65. Armario P, Hernández R, Martín-Baranera M, Almendros MC, Andreu N, Ruigómez J, et al. Ausencia de relación entre insulinemia y afectación orgánica en hipertensos no tratados grados 1 y 2. *Hipertensión*. 2001;18:110-7.
66. Armario P, Hernández R, Gasulla JM, Alonso A, Tresserras R, Pardell H. Prevalencia de hipertensión arterial en L'Hospitalet de Llobregat. Evolución de la tasa de control entre 1981 y 1987. *Med Clin (Barc)*. 1990;94:570-5.
67. Banegas JR, Rodríguez-Artalejo F, Guallar P. Number needed to treat to gain one controlled hypertensive. *Curr Hypertens Rep*. 2004;6:75-6.
68. Krousel-Wood MA, Muntner P, He J, Whelton PK. Primary prevention of essential hypertension. *Med Clin North Am*. 2004;88:223-38.
69. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet*. 1990;335:765-74.
70. Collins R, Peto R, MacMahon S, Hebert P, Fiebich NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. *Lancet*. 1990;335:827-38.
71. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362:1527-35.
72. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. *J Hypertens*. 2003;21:1055-76.
73. Jessup M, Brozena S. Heart failure. *N Engl J Med*. 2003;348:2007-18.
74. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with post-discharge support for older patients with congestive heart failure. *JAMA*. 2004;291:1358-67.
75. Baker DW, Goldstein S, Chim MH, Gregoratos G, Cinquegrani MP, Jessup ML, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. *Circulation*. 2001;104:2118-50.
76. Marín R, Gorostidi M, Pobes A. Hipertensión arterial y enfermedad vascular renal: nefroangioesclerosis. *Nefrología*. 2002;22 Suppl 1:36-45.
77. Palmer BF. Renal dysfunction complicating the treatment of hypertension. *N Engl J Med*. 2002;347:1256-61.
78. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). *Eur J Cardiovasc Prev Rehab*. 2003;10 Suppl 1:S1-78.
79. O'Donnell CJ. Family history, subclinical atherosclerosis, and coronary heart disease risk. Barriers and opportunities for the use of family history information in risk prediction and prevention. *Circulation*. 2004;110:2074-6.
80. Szczech R, Hering D, Narkiewicz K. Smoking and cardiovascular risk: new mechanisms and further evidence for a 'guilty' verdict. *J Hypertens*. 2004;22:31-4.
81. Pardell Alenta H, Armario García P, Hernández del Rey R. Tabaco, presión arterial y riesgo cardiovascular. *Hipertensión*. 2003;20:226-33.
82. Pardell H, Tresserras R, Salto E, Armario P, Hernandez del Rey R. Management of hypertensive who smokes. *Drugs*. 1998;56:177-87.
83. Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486-97.
84. Luque Otero M, Martell Claros N. Hipertensión arterial y síndrome metabólico. *Med Clin (Barc)*. 2004;123:707-11.
85. Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults; Executive summary. *Am J Clin Nutr*. 1998;68:899-917.
86. Álvarez León EE, Ribas Barba L, Serra Majem L. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. *Med Clin (Barc)*. 2003;120:172-4.
87. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmen R. Cuantificación de insulinorresistencia con los valores de insulina basal e índice HOMA en una población no diabética. *Med Clin (Barc)*. 2001;117:530-3.
88. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of US populations, 1971-1993. *Diabetes Care*. 1998;21:1138-45.
89. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998;339:229-34.
90. Lee CD, Folsom AR, Pankow JS, Brancati FL, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Circulation*. 2004;109:855-60.
91. Khaw KT, Wareham N, Bingam S, Luben R, Welch A. Association of Hemoglobin A1c with cardiovascular disease and mortality in adults. The European Prospective investigation into cancer in Norfolk. *Ann Intern Med*. 2004;141:413-20.
92. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med*. 2004;141:321-31.
93. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation*. 2003;107:363-9.
94. Danesh J, Wheeler JG, Hirschfeld GM, Shinichi E, Eiriksdottir G, Rumley A, et al. C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med*. 2004;350:1387-97.
95. Tall AR. C-Reactive protein reassessed. *N Engl J Med*. 2004;350:1450-2.
96. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med*. 2005;352:20-8.
97. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-Reactive protein, and coronary artery disease. *N Engl J Med*. 2005;352:29-38.
98. Ehrenstein MR, Jury EC, Mauri C. Statins for atherosclerosis. As good as it gets? *N Engl J Med*. 2005;352:73-5.
99. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in nondiabetic subjects. Islington Diabetes Survey. *Lancet*. 1988;2:530-3.
100. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Sharling H, et al. Very low levels of microalbuminuria are associated with increases risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. *Circulation*. 2004;110:32-5.
101. Redón J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. *J Hypertens*. 2002;20:353-5.
102. Agewall S, Wikstrand J, Ljungman S, Fagerberg B, for the Risk Factor Intervention Study Group. Usefulness of microalbuminuria in predicting microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. *Am J Cardiol*. 1997;80:160-9.
103. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. *BMJ*. 1990;300:297-300.

104. Ljungman S, Wikstrand J, Harthford M, Berglund G. Urinary albumin excretion: a predictor of risk of cardiovascular disease. *Am J Hypertens*. 1996;9:770-8.
105. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA*. 2001;286:421-6.
106. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. *J Intern Med*. 2004;255:247-56.
107. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. *Am J Hypertens*. 2004;17:986-93.
108. Palatini P, Graniero GR, Mormino P, Mattarei M, Sanzuol F, Cignaco GB et al. Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study). *J Hypertens*. 1996;9:334-41.
109. Pontremolli R, Sofía A, Ravera M, Nicoletta C, Viazzi F, Tirrotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC Study. *Hypertension*. 1997;30:1135-43.
110. Hoegholm A, Bang LI, Kristensen KS, Nielsen JW, Holm J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension and normotension. *Hypertension*. 1994;24:101-5.
111. Martínez MA, Moreno A, Aguirre de Cáncer A, Cabrera R, Rocha R, Torre A, Nevado A et al, on behalf of the MAPA-Madrid Working Group. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. *J Hypertens*. 2001;19:319-26.
112. Armario P, Hernández del Rey R, Torres G, Martín-Baranera M, Almendros MC, Pardell H. Reacción entre reactividad cardiovascular al estrés mental y afectación temprana de órganos diana en la HTA ligera no tratada. *Med Clin (Barc)*. 1999;113:401-6.
113. Armario García P, Hernández del Rey R, Pardell Alenta H. Microalbuminuria. Prevalencia y su significado en la HTA. *Hipertensión* 1999;16:251-4.
114. Palatini P, Mormino P, Santonastaso M, Mos L, Dal Follo M, Zanata G, et al. Target organ damage in stage I hypertensive subjects with white coat and sustained hypertension. Results from the HARVEST study. *Hypertension*. 1998;31:57-63.
115. Hernández del Rey R, Armario P, Martín-Baranera M, Torres G, Sánchez P, Pardell H. The influence of two different normal limits of ambulatory blood pressure on the assessment of white coat hypertension and target organ damage. *Am J Hypertens*. 1998;11:225A.
116. Segura de la Morena J, García Donaire JA, Ruilope Urioste LM. Relevancia de la insuficiencia renal en el pronóstico de los pacientes con hipertensión arterial esencial. *Med Clin (Barc)*. 2004;123:143-8.
117. Cockcroft DW, Gault MH. Prediction of creatinina clearance from serum creatinina. *Nephron*. 1976;16:31-41.
118. Levey AS, Bosch J, Lewis JB, Greene T, Rogers N, Roth D for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinina: a new prediction equation. *Ann Intern Med*. 1999;130:461-70.
119. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med*. 2003;139:137-47.
120. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalisation. *N Engl J Med*. 2004;351:1296-305.
121. Rodríguez-Artalejo F, Banegas Banegas JR. De la ecuación de Framingham a la prevención cardiovascular. *Med Clin (Barc)*. 2003;121:334-6.
122. Bastuji-Garin S, Deverly A, Moyse D, Castaigne A, Mancia G, De Leeuw PW, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. *J Hypertens*. 2002;20:1973-80.
123. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, de Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J*. 2003;24:987-1003.
124. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A on behalf of the APROS Investigators. Role of echocardiography in stratifying in patients with essential hypertension: the Assessment of Prognostic Risk Observational Study. *J Hypertens*. 2002;20:1307-14.
125. Schillaci G, De Simone G, Reboldi G, Porcellati C, Devereux RB, Verdecchia P. Change in cardiovascular profile by echocardiography in low-or-medium risk hypertension. *J Hypertens*. 2002;20:1519-25.
126. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovás J, et al. An adaptation of the Framingham coronary risk function to southern Europe Mediterranean areas. *J Epidemiol Community Health*. 2003;57:634-8.
127. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovás J, Cerdón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. *Rev Esp Cardiol*. 2003;56:253-61.
128. Ramos R, Solanas P, Cerdón F, Rohlfs I, Elosua R, Sala J, et al. Comparación de la función original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional. *Med Clin (Barc)*. 2003;121:521-6.
129. Brotons C, Cascant P, Ribera A, Moral I, Permanyer G. Utilidad de la medición del riesgo a partir de la ecuación del estudio de Framingham: estudio de casos y controles. *Med Clin (Barc)*. 2003;121:327-30.
130. Maiques Galán A, Antón García F, Frach Taix M, Ros AX, Martí A, Collado Gil A. Riesgo cardiovascular del SCORE comparado con el Framingham. Consecuencias del cambio propuesto por las Sociedades Europeas. *Med Clin (Barc)*. 2004;123:681-5.
131. Aranceta J, Pérez Rodrigo C, Foz Salas M, Mantilla T, Serra Majem L, Moreno B, et al. Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICA. *Med Clin (Barc)*. 2004;123:686-91.
132. Yusuf S, Hawken S, Ounpuu S, Avezum A, Lanas F, McQueen M, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364:937-52.
133. Rosengren A, Hawken S, Ounpuu S, Silwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11.119 cases and 13648 controls from 52 countries (INTERHEART STUDY): case-control study. *Lancet*. 2004;364:953-62.
134. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *J Hypertens*. 2003;21:821-48.
135. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in Humans: A statement for professionals from the Subcommittee of Professionals and Public Education of The American Heart Association Council on High Blood Pressure Research. *Hypertension*. 2005;45:142-61.
136. Pickering TG. The influence of daily activity on ambulatory blood pressure. *Am Heart J*. 1988;116:1141-6.
137. Bailey RH, Bauer JH. A review of common errors in the indirect measurement of blood pressure. *Sphygmomanometer*. *Arch Intern Med*. 1993;153:27-41.
138. Pickering TG, Devereux RB, Gerin W, James GD, Pieper C, Schlüssel YR, Schnall PL. The role of behavioral factors in white coat and sustained hypertension. *J Hypertens*. Suppl.1990;8:S141-7.
139. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. *Hypertension*. 1987;9:209-15.

140. Bottini P, Carr A, Prisant L, Rhoades R. Variability and similarity of manual office and automated blood pressures. *J Clin Pharmacol*. 1992;32:614-9.
141. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? *JAMA*. 1988;259:225-8.
142. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. American Society of Hypertension. *Am J Hypertens*. 1992;5:207-9.
143. Kaplan NM. Measurement of blood pressure. En: Kaplan NM, editor. *Clinical hypertension*. 8th ed. Baltimore: Williams and Wilkins; 1994. p. 25-45.
144. Lebl ME, Holzgreve H, Schultz M, Crispin A, Bogner J. The effect of clothes on Sphygmomanometric and oscillometric blood pressure measurement. *Blood Pressure*. 2004;13:279-82.
145. Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, et al. "White coat" versus "sustained" borderline I. White-coat versus sustained borderline hypertension in Tecumseh, Michigan. *Hypertension*. 1990;16:617-23.
146. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, et al. Home blood pressure measurement has a stronger predictive power for mortality that does screening blood pressure: a population-based observation in Ohasama, Japan. *J Hypertens*. 1998;16:971-97.
147. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. *JAMA*. 2004;291:1342-9.
148. Proceedings from the First International Consensus Conference on Self-blood Pressure Measurement. *Blood Press Monit*. 2000;5:91-149.
149. Asmar R, Zanchetti A. Guidelines for the use of self blood pressure monitoring: a summary report of the first international consensus conference. *J Hypertens*. 2000;18:493-508.
150. Staessen JA, Thijs L. Development of diagnostic thresholds for automated self-measurement of blood pressure in adults, First International Consensus Conference on Blood Pressure Self-Measurement. *Blood Press Monit*. 2000;5:101-9.
151. Stergiou G, Mengden T, Padfield P, Parati G, O'Brien E. Self monitoring of blood pressure at home. *BMJ*. 2004;329:870-1.
152. <http://www.dablededucational.com> (acceso el 19 febrero-2005).
153. http://www.hyp.ac.uk/bhs/bp_monitors/automatic.htm (acceso el 19-febrero-2005).
154. Kikuya M, Chonan K, Imai Y, Goto E, Ishii M. Accuracy and reliability of wrist-cuff devices for self measurement of blood pressure. *J Hypertens*. 2002;20:629-38.
155. Stergiou G, Alamara C, Kalkana C, Vaindirilis IN, Stefanidis CJ, Dacou-Voutetakis C, et al. Out-of-office blood pressure in children and adolescents: disparate findings by using home or ambulatory monitoring. *Am J Med*. 2004;17:869-75.
156. Pickering, TG, for an American Society of Hypertension Ad Hoc Panel. Recommendations for use of home (self) and ambulatory blood pressure monitoring. *Am J Hypertens*. 1995;9:1-11.
157. Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D. Comparison of agreement between different measures of blood pressure in primary care and daytime ambulatory blood pressure. *BMJ*. 2002;325:254-9.
158. Cuspidi C, Meani S, Fusi V, Salerno M, Valerio C, Severgnini B, et al. Home blood pressure measurement and its relationship with blood pressure control in a large selected cohort. *J Hum Hypertens*. 2004;18:725-31.
159. Staessen J, Den Hond E, Celis H, Fagard R, Keary L, Vandenhoven G, et al. Antihypertensive treatment Based on blood pressure measurement at home or in the physician's office. *JAMA*. 2004;291:955-64.
160. División JA, Sanchis C, Artigao LM, Carbayo JA, Carrión-Valero L, López de Coca, et al. Grupo de estudio de enfermedades vasculares de Albacete (GEVA). Home-based self-measurement of blood pressure: a proposal using new reference values (the PURAS study). *Blood Press Monit*. 2004;9:211-8.
161. Whelton A. Application of ambulatory blood pressure monitoring to clinical therapeutic decisions in hypertension. *J Hypertens Suppl*. 1991;9:S21-25.
162. Pickering, TG. A review of national guidelines on the clinical use of ambulatory blood pressure monitoring. *Blood Press Monit*. 1996;1:151-6.
163. Schettini C, Bianchi M, Nieto F, Sandoya E, Senra H, the Hypertension Working Group. Ambulatory blood pressure: normality and comparison with other measurements. *Hypertension*. 1999;34 Pt 2:818-82.
164. Verdecchia P, Clement D, Fagard. Target organ damage, morbidity and mortality. *Blood Press Monit*. 1999;4:303-17.
165. Verdecchia P, Porcellati C, Schillaci C, Borglioni C, Ciucci A, Batistelli M. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. *Hypertension*. 1994;24:793-801.
166. Perloff D, Sokolow M, Cowan R, Juster R. Prognostic value of ambulatory blood pressure measurements: further analyses. *J Hypertens*. 1989;7 Suppl 3:s3-10.
167. Khattar RS, Swales JD, Banfield A, Dore C, Senior R, Lahiri A. Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension. *Circulation*. 1999;100:1071-6.
168. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. *J Hypertens*. 1997;15:357-64.
169. Staessen J, Thijs L, Fagard R, O'Brien E, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. *JAMA*. 1999;282:539-46.
170. Redón J, Campo C, Narciso ML. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. *Hypertension*. 1998;31:712-8.
171. Bjorklund K, Lind L, Zethelius B, Berglund L, Lithell H. Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men. *J Hypertens*. 2004;22:1691-7.
172. Clement D, de Buyzere M, de Bacquer D, de Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. *N Engl J Med*. 2003;348:2407-15.
173. Jula A, Puukka P, Karanko H. Multiple clinic and home blood pressure measurements versus ambulatory blood pressure monitoring. *Hypertension*. 1999;34:261-6.
174. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG on behalf of the European Hypertension Society, Blood Pressure measuring devices: recommendations of the European Society of Hypertension. *BMJ*. 2001;322:531-5.
175. Hermida RC, Calvo C, Ayala DE, Fernández JR, Ruilope LM, López JE. Evaluation of the extent and duration of the ABPM effect in hypertensive patients. *J Am Coll cardiol*. 2002;40:710-7.
176. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Blood Pressure Monitoring. Task force V: White-coat hypertension. *Blood Press Monit*. 1999;4:333-41.
177. Richards C, Sutherland M, Gough K, Padfield PL. Direct access to ambulatory blood pressure monitoring: The Edinburgh experience. *Blood Press Monit*. 2004;9:287-291.
178. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien E, Fagard R, et al. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. *JAMA* 1997;278: 1065-72.
179. Pierdomenico SD, Lapenna D, Bucci A, Di Iorio A, Neri M, Cuccurullo F, et al. Cardiovascular and renal events in uncomplicated mild hypertensive patients with sustained and white coat hypertension. *Am J Hypertens*. 2004;17:876-81.

180. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshida S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. *J Cardiol.* 2002;39:52-4.
181. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. *Circulation.* 1998;98:1892-7.
182. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, et al. Short- and Long-Term Incidence of Stroke in White-Coat Hypertension. *Hypertension* 2005; 45:203-208
183. Bjorklund K, Lind L, Zethelius B, Andren B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. *Circulation.* 2003;107:1297-302.
184. Palatini P, Winnicki M, Santonastaso M, Mos L, Longo D, Zaetta V, et al. Prevalence and clinical significance of isolated ambulatory hypertension in young subjects screened for stage 1 hypertension. *Hypertension.* 2004;44: 170-4.
185. Ungar A, Pepe G, Monami M, Lambertucci L, Torrini M, Baldasseroni S, et al. Isolated ambulatory hypertension is common in outpatients referred to a hypertension centre. *J Hum Hypertens* 2004; 18(12):897-903.
186. Omvik P, Gerhardsen G. The Norwegian office-, home-, and ambulatory blood pressure study (NOHA). *Blood Press.* 2003;12:211-9.
187. Vinyoles E, de la Figuera M. La presión ambulatoria de los hipertensos con buen control tensional en la consulta. *Hipertensión.* 2003;20:295-9.
188. Hermida RC, Ayala DE, Fernández JR, Mojon A, Iglesias M. Evaluación prospectiva del índice hiperbárico para el diagnóstico de la hipertensión gestacional y la preeclampsia. *Med Clin (Barc).* 2004;123:161-8.
189. Zweiker R, Eber B, Schumacher M. Nondipping related to cardiovascular events in essential hypertensive patients. *Acta Med Aust.* 1994;21:86-9.
190. Kario K, Pickering TG, Matsuo T, Hoshida S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. *Hypertension.* 2001;38:852-7.
191. Ohkubo T, Imai Y, Tsuji T, Nagai K, Watanabe N, Minami N, et al. Relation between nocturnal decline in blood pressure and mortality: the Ohasama study. *Am J Hypertens.* 1997;10:1201-7.
192. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognosis significance of the nocturnal decline in blood pressure in individuals with and without high 24 h blood pressure: the Ohasama study. *J Hypertens.* 2002;20:2183-9.
193. Mochizuki Y, Okutani M, Dongfeng Y, Iwasaki H, Takusagawa M, Kohno I, et al. Limited reproducibility of circadian variation in blood pressure dippers and nondippers. *Am J Hypertens.* 1998;11:403-9.
194. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, et al. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. *Chronobiol Int.* 2004;21:277-96.
195. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernandez JR, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. *Hypertension.* 2003;42:283-90.
196. Hermida RC, Ayala DE, Calvo C, López JE, Fernández JR, Mojon A, et al. Response: Aspirin Administered at Bedtime as Opposed to Upon Wakening Has an Effect on Ambulatory Blood Pressure: Further Evidence. *Hypertension.* 2004 Feb 16
197. De la Sierra A, Coca A. Evaluación clínica y diagnóstico diferencial del paciente hipertenso. En: Coca A, de la Sierra A, editores. Decisiones clínicas y terapéuticas en el paciente hipertenso. 3.ª ed. Barcelona: Editorial Médica JIMS; 2002. p. 59-81.
198. Messerli FH, Frohlich ED. High blood pressure, a side effect of drugs, poison and food. *Arch Intern Med.* 1979; 139:682-7.
199. Bulpitt CJ, Dollery CT, Crane S. Change in symptoms in hypertensive patients after referral to hospital clinic. *Br Heart J.* 1976;38:121-8.
200. Kruszewski P, Bieniaszewski L, Neubauer J, Krupa-Wojciechowska B. Headache in patients with mild to moderate hypertension is generally not associated with simultaneous blood pressure elevation. *J Hypertens.* 2000;18:437-44.
201. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz CA, et al. Body size and fat distribution as predictors of coronary heart disease among middle aged and older US men. *Am J Epidemiol.* 1995;141:1117-27.
202. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA.* 2002;288:2709-16.
203. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. *Circulation.* 2002;106:3143-421.
204. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. *Diabet Med.* 1998;15: 539-53.
205. Ross EJ, Lynch DC. Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. *Lancet.* 1982;2:646-9.
206. Kalff V, Shapiro B, Lloyd R, Sisson JC, Holland K, Nakajo M, et al. Spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis. *Arch Intern Med.* 1982; 142:2092-6.
207. Belch JFF, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Critical issues in peripheral arterial disease detection and management. A call to action. *Arch Intern Med.* 2003;163:884-92.
208. Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. *J Am Soc Nephrol.* 2000;11: A0828.
209. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. *J Am Soc Nephrol.* 2001;12:218-25.
210. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. *Hypertension.* 2000;35:1025-30.
211. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet.* 2003;361:1149-58.
212. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2004;27 Suppl 1;S5-10.
213. De la Sierra A, Ruilope LM. Treatment of hypertension in diabetes mellitus. *Current Hypertension Reports.* 2000;2: 335-42.
214. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. *JAMA.* 2000;283:2404-10.
215. Sibai BM. Treatment of hypertension in pregnant women. *N Engl J Med.* 1996;335:257-65.
216. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation.* 2002;105:1125-43.
217. Viberti GC, Hill RD, Jarret RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. *Lancet.* 1982;1:1430-2.
218. Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, Chaudhary BS, et al. Electrocardiographic detection

- of left ventricular hypertrophy: development and prospective validation of improved criteria. *J Am Coll Cardiol*. 1985;6:572-80.
219. Levy D, Solomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. *Circulation*. 1994;90:1786-93.
 220. Reichek N, Devereux RB. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. *Circulation*. 1981;63:1391-8.
 221. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs J, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol*. 1986;57:450-8.
 222. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med*. 1990;322:1561-6.
 223. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. *Ann Intern Med*. 1991;114:345-52.
 224. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieler RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. *Am J Med*. 2003;115:41-6.
 225. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:995-1003.
 226. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. *N Engl J Med*. 1999;340:14-22.
 227. London GM, Cohn JN. Prognostic application of arterial stiffness: task forces. *Am J Hypertens*. 2002;15:754-8.
 228. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. *Circulation*. 2001;104:191-6.
 229. Sierra C, de La Sierra A, Mercader J, Gómez-Angelats E, Urbano-Márquez A, Coca A. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. *J Hypertens*. 2002;20:519-24.
 230. Miyao S, Takano A, Teramoto J, Takahashi A. Leukoaraiosis in relation to prognosis for patients with lacunar infarction. *Stroke*. 1992;23:1434-8.
 231. Safian RD, Textor SC. Renal-artery stenosis. *N Engl J Med*. 2001;344:431-42.
 232. Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, Maki JH, Leiner T, et al. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. *Ann Intern Med*. 2004;141:674-82.
 233. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. *J Hypertens*. 2004;22:863-9.
 234. Grumbach MM, Biller BMK, Braunstein GD, Campbell KK, Carney A, Godley PA, et al. Management of the clinically inapparent adrenal mass (incidentaloma). *Ann Intern Med*. 2003;138:424-9.
 235. Pacack K, Linehan WM, Eisenhofer G, Walthers MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. *Ann Intern Med*. 2001;134:315-29.
 236. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. *J Human Hypertens*. 2004;18:139-85.
 237. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903-13.
 238. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trial. *Lancet*. 2000;355:1955-64.
 239. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. *Lancet*. 2001;358:1305-15.
 240. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet*. 1998;351:1755-62.
 241. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet*. 2001;358:1033-41.
 242. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342:145-53.
 243. Vokó Z, Bots ML, Hofman A, Koudstaal PJ, Witterman JCM, Breteler MMB. J-shaped relation between blood pressure and stroke in treated hypertensives. *Hypertension*. 1999;34:1181-5.
 244. Somes GW, Pahor M, Shorr IR, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. *Arch Intern Med*. 1999;159:2004-9.
 245. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2000;283:1967-75.
 246. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA*. 2002;288:2981-97.
 247. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med*. 2001;345:1291-7.
 248. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. *BMJ*. 1998;317:703-13.
 249. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet*. 2000;355:253-9.
 250. Estacio RO, Jeffers BW, Hiatt WR, Biggstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med*. 1998;338:645-52.
 251. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. *Kidney Int*. 2002;61:1086-97.
 252. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med*. 1994;330:877-84.
 253. Peterson JC, Adler A, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med*. 1995;123:754-62.

254. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. *JAMA*. 2002; 288:2421-31.
255. Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet*. 2000;355:865-72.
256. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. The effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. Results from a meta-analysis of individual patient data in randomised controlled trials. *Ann Intern Med*. 1997;126:761-7.
257. MRC Working Party. Medical Research Council trial of treatment of mild hypertension: principal results. *BMJ*. 1985; 291:97-104.
258. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. *BMJ*. 1992;304:405-12.
259. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). *J Hypertens*. 1985;3:379-392.
260. Wilhelmssen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. *J Hypertens*. 1987;5:561-72.
261. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G, on behalf of the Advisory Committee. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. *JAMA*. 1988;259:1976-82.
262. Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, Eliasson K, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. *Hypertension*. 1991;17:579-88.
263. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effects of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet*. 1999;353:611-6.
264. Hansson L, Lindholm LH, Ekblom T, Dahlöf B, Lanke J, Scherstén B, et al, for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet*. 1999;345:1751-6.
265. National Intervention Cooperative Study in the Elderly Hypertensive Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. *Hypertension*. 1999;34:1129-33.
266. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syversten JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet*. 2000; 356:359-65.
267. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet*. 2000;356:366-72.
268. Black HR, Elliott WJ, Grandist G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. *JAMA*. 2003;289:2073-82.
269. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al, for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med*. 2003;348:583-92.
270. Lithell H, Hansson L, Skogg I, Elmfeldt D, Hofman A, Olofsson B, et al, for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. *J Hypertens*. 2003;21:875-86.
271. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*. 2001;345:861-9.
272. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type diabetes. *N Engl J Med*. 2001;345:851-60.
273. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med*. 2001;345:870-8.
274. Viberti G, Wheeldon NM; for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. *Circulation*. 2002;106:672-8.
275. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. *Circulation*. 1998;97:48-54.
276. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Cannon-Terris M, Carr AA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. *JAMA*. 1996;276: 785-91.
277. Zanchetti A, Agabiti-Rosei E, Dal Palu C, Leonetti G, Maggiani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. *J Hypertens*. 1998;16:1667-76.
278. Simon A, Garipey J, Moyses D, Levenson J. Differential effects of nifedipine and co-amlozide on the progression of early carotid wall changes. *Circulation*. 2001;103:2949-54.
279. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. *Circulation*. 2002; 106:2422-7.
280. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al, for the AtheroGene Investigators. Circulating cell adhesion molecules and death in patients with coronary artery disease. *Circulation*. 2001;104:1336-42.
281. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. *Circulation*. 2000;101:1653-9.
282. Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. *Br J Biomed Sci*. 2003;60:191-6.
283. Rahman ST, Lauten WB, Khan QA, Navalkar S, Parthasarathy S, Khan BV. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure. *Am J Cardiol*. 2002;89: 686-90.
284. Fliser D, Buchholz K, Haller H, for the European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. *Circulation*. 2004; 110:1103-7.
285. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. *Hypertension*. 2004;43:963-9.
286. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. *J Hypertens*. 2004;22: 1845-7.

287. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. Practice guidelines writing committee. *J Hypertens*. 2003; 21:1779-86.
288. Viazzi F, Parodi D, Leoncini G, Vettoretti S, Ratto E, Vaccaro V, et al. Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. *J Hypertens*. 2004;22:907-13.
289. Stamler J. Epidemiologic findings on body mass and blood pressure in adults. *Ann Epidemiol*. 1991;1:347-62.
290. The Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. *JAMA*. 1992;267:1213-20.
291. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. *Arch Intern Med*. 1997;157:657-67.
292. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. *Hypertension*. 2000;35:544-9.
293. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettlinger WH, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. *JAMA*. 1998;279:839-46.
294. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2003;42:878-84.
295. Jones DW, Miller ME, Wofford MR, Anderson DC, Cameron ME, Willoughby DL, et al. The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. *Am J Hypertens*. 1999;12:1175-80.
296. Reid CM, Dart AM, Dewar EM, Jennings GL. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. *J Hypertens*. 1994;12:291-301.
297. Puddey IB, Parker M, Beilin LJ, Vandongen R, Masarei JR. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. *Hipertensión*. 1992;20:533-41.
298. O'Meara S, Riemsma R, Shirran L, Mather L, Ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. *Obes Rev*. 2004;5:51-68.
299. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. *Arch Intern Med*. 2004;164:994-1003.
300. De la Sierra A. La restricción salina es una medida de utilidad en la prevención y tratamiento de la hipertensión arterial. *Hipertensión*. 2004;21:317-21.
301. Elliott P, Stamler J, Nichols R, Dyer AR, Stamler R, Kestelot H, et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. *BMJ*. 1996;312:1249-53.
302. Denton D, Weisinger R, Mundy NI, Wickings EJ, Dixon A, Moisson P, et al. The effect of increased salt intake on blood pressure of chimpanzees. *Nat Med*. 1995;1:1009-16.
303. Tuomiletho J, Jousilahti P, Rastenyte D, Moltchanov V, Tanskanen A, Pietinen P. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. *Lancet*. 2001;357:848-51.
304. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. *JAMA*. 1999;282:2027-34.
305. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. *Am J Clin Nutr*. 1997;65 Suppl:S643-51.
306. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. *N Engl J Med*. 2001;344:3-10.
307. Klatsky AL. Alcohol and hypertension. *Clin Chim Acta*. 1996;246:91-105.
308. Fuchs FD, Chambless LE, Whelton PK, Nieto FJ, Heiss G. Alcohol consumption and the incidence of hypertension: The Atherosclerosis Risk in Communities Study. *Hypertension*. 2001;37:1242-50.
309. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged British men. *Stroke* 1996; 27:1033-9.
310. Aguilera MT, de la Sierra A, Coca A, Estruch R, Fernández-Sola J, Urbano-Márquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. *Hypertension*. 1999;33:653-7.
311. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2001;38:1112-7.
312. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA Jr, Stampfer MJ, Willett WC, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. *N Engl J Med*. 2003;348:109-18.
313. Malinski MK, Sesso HD, López-Jiménez F, Buring JE, Gaziano JM. Alcohol consumption and cardiovascular disease mortality in hypertensive men. *Arch Intern Med*. 2004; 164:623-8.
314. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. *N Engl J Med*. 1997;336:1117-24.
315. Knuops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. *JAMA*. 2004;292:1433-9.
316. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. *Ann Intern Med*. 2002;136:493-503.
317. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, Waugh R, Georgiades A, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. *Arch Intern Med*. 2000;160:1947-58.
318. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. *BMJ*. 1994;309:901-11.
319. Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR. Association between smoking and blood pressure: evidence from the health survey for England. *Hypertension*. 2001;37:187-93.
320. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. *Arch Intern Med*. 1995;155:1933-41.
321. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. *JAMA*. 2000; 283:3244-54.
322. Kaplan NM. Treatment of hypertension: drug therapy. En: Kaplan NM, editor. *Clinical Hypertension*. 7th ed. Baltimore: Williams & Wilkins; 1998. p. 181-263.
323. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). *Arch Intern Med*. 1993;153:154-83.
324. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and

- Treatment of High Blood Pressure. JNC 7 - Complete version. Hypertension. 2003;42:1206-52.
325. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization / International Society of Hypertension meeting. J Hypertens. 1993;11:905-18.
 326. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:2047-9.
 327. Alcazár JM. Tratamiento de la hipertensión arterial. En: Hernando L, Aljama P, Arias M, Caramelo C, Egido J, Lamas S, editores. Nefrología Clínica. Madrid: Editorial Médica Panamericana S.A.; 2003. p. 210-8.
 328. Flack JM, Cushman W. Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med. 1996;101:535-603.
 329. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276:1886-92.
 330. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, et al, for The Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17.
 331. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543-51.
 332. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ. 2003;326:681-4.
 333. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-74.
 334. Pepine CJ, Cooper-DeHoff RM. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 2004;44:509-12.
 335. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsí P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8.
 336. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-55.
 337. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomised trial. Lancet. 1999;342:9-13.
 338. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
 339. Flather MD, Shibata MC, Coats AJ, van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.
 340. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. The CAPRICORN randomized trial. Lancet 2001;357:1385-90.
 341. Escasany AA, Durán M, Arnau JM, Rodríguez D, Fadini ED, Casas J, et al. Tratamiento médico de la insuficiencia cardiaca en la evidencia. Rev Esp Cardiol. 2001;54:715-34.
 342. Bristow MR. β adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-69.
 343. Farrell MH, Foody JAM, Krumholz HM. β blockers in heart failure. JAMA. 2002;287:890-7.
 344. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. The Task Force on β blockers of the European Society of Cardiology. Expert consensus document on β -adrenergic receptor blockers. Eur Heart J. 2004;25:1341-62.
 345. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al, for the Systolic Hypertension in Europe Trial Investigators. Effect of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.
 346. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-5.
 347. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
 348. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet. 2000;356:1949-54.
 349. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14:1237-45.
 350. Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med. 2000;160:211-20.
 351. Packer M, O'Conner CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-14.
 352. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME, et al, for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-10.
 353. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al, on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet. 2004;364:849-57.
 354. Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens. 1997;15:1337-44.
 355. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-20.
 356. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al, on behalf of the HOPE Investigators. Use of ramipril in preventing stroke: double blind randomized trial. BMJ. 2002;324:699-702.
 357. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in PEACE? N Engl J Med. 2004;351:2115-7.
 358. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-68.
 359. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-92.
 360. Ravid M, Brosh D, Levi Z, Bar-Dayyan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982-8.

361. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. *Ann Intern Med.* 1993;118:577-81.
362. Viberti G, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. *JAMA.* 1994;271:275-9.
363. Gæde P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet.* 1999;353:617-22.
364. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors. A meta-analysis of individual patient data. *Ann Intern Med.* 2001;134:370-9.
365. Parving HH, Hovind P, Rossing K, Andersen S. Evolving strategies for renoprotection: diabetic nephropathy. *Curr Opin Nephrol Hypertens.* 2001;10:515-22.
366. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med.* 1993;329:1456-2.
367. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med.* 2003;348:383-93.
368. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Montolesse M, et al and the Angiotensin-converting-enzyme Inhibition in Progressive Renal Insufficiency study group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of renal insufficiency. *N Engl J Med.* 1996;334:939-45.
369. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet.* 1997;349:1857-63.
370. Segura J, Campo C, Rodicio JL, Ruilope LM. ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. *Hypertension.* 2001;38:645-9.
371. Marín R, Ruilope LM, Aljama P, Aranda P, Segura J, Díez J, on behalf of the investigators of the ESPIRAL study. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. *J Hypertension.* 2001;19:1871-6.
372. Jaffar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al, for the ACE Inhibition in Progressive Renal Disease Study Group. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. *Ann Intern Med.* 2001;135:73-87.
373. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, et al, for the AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. *Ann Intern Med.* 2003;139:244-52.
374. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med.* 1987;316:1429-35.
375. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med.* 1991;325:293-302.
376. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. *N Engl J Med.* 1992;327:669-77.
377. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet.* 1993;342:821-8.
378. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med.* 1995;333:1670-6.
379. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. *Lancet.* 1994;343:1115-22.
380. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. The Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors. *Eur Heart J.* 2004;25:1454-70.
381. Burnier M, Brunner HR. Angiotensin II receptor antagonists. *Lancet.* 2000;355:637-45.
382. Tamargo J. Antagonistas de los receptores de la angiotensina II. *Med Clin (Barc).* 2000;114 Suppl 1:S6-13.
383. Gorostidi M, Concejo B, Prieto MA, Marín R. Antagonistas de los receptores de la angiotensina II. Una revisión farmacoterapéutica. *Hipertensión.* 2002;19:129-38.
384. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al, for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet.* 2002;359:1004-10.
385. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. *JAMA.* 2002;288:1491-8.
386. Pitt B, Poole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. *Lancet.* 2000;355:1582-7.
387. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med.* 2001;345:1667-75.
388. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. *Lancet.* 2003;362:767-71.
389. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. *Lancet.* 2003;362:772-6.
390. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM Preserved Trial. *Lancet.* 2003;362:777-81.
391. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. *Lancet.* 2002;360:752-60.
392. American Diabetes Association. Diabetic nephropathy. *Diabetes Care.* 2005;28 Suppl 1:S4-3.
393. Praga M, Fernández-Andrade C, Luño J, Arias M, Poveda R, Mora J, et al: Antiproteinuric efficacy of losartan in comparison with amlodipine in nondiabetic proteinuric renal disease: a double-blind, randomized clinical trial. *Nephrol Dial Transplant.* 2003;18:1806-13.

394. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. *Lancet*. 2003;361:117-24.
395. Lepor H, Kaplan SA, Klimberg I, Mogley D. Doxazosin for benign prostatic hyperplasia. Long-term efficacy and safety in hypertensive and normotensive patients. *J Urol*. 1997;157:524-30.
396. Ruilope L M, Suárez C. Las asociaciones de fármacos: alternativa en el tratamiento de la hipertensión arterial. *Med Clin*. 1995;104:620-2.
397. Materson B, Reda D, Preston R, Cushman W, Massie BM, Freis ED, et al. Response to a second single antihypertensive agents use as monotherapy for a hypertension after failure of the initial drug. *Arch Intern Med*. 1995;155:1757-62.
398. Graves JW. Management of difficult-to-control hypertension. *Mayo Clin Proc*. 2000;75:278-84.
399. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? *Am J Hypertens*. 2001;14:1263-9.
400. Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. *BMJ*. 2000;321:13-7.
401. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. *Lancet*. 2001;357:89-95.
402. Hebert PR, Hennekens CH. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. *Arch Intern Med*. 2000;160:3123-7.
403. Lip GYH, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy. *J Intern Med*. 2001;249:205-14.
404. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. *Ann Intern Med*. 2002;136:157-60.
405. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2002;136:161-71.
406. Lauer MS. Aspirin for primary prevention of coronary events. *N Engl J Med*. 2002;346:1468-74.
407. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer R, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med*. 1995;333:1301-7.
408. Downs J, Clearfield M, Wers S, Whitney E, Shapiro DR, Beere PA, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. *JAMA*. 1998;279:1615-22.
409. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383-9.
410. Sacks FM, Pfeffer M, Moye LA, Rouleau JL, Rutherford JP, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med*. 1996;335:1001-9.
411. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7-22.
412. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002;360:1623-30.
413. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364:685-96.
414. Grundy SM, Cleeman JJ, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110:227-39.
415. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. *N Engl J Med*. 2005;352:1425-35.
416. Márquez E, Casado JJ, Martínez M, Moreno JP, Fernández A, Villar J. Análisis de la influencia del cumplimiento terapéutico farmacológico en las presiones arteriales y grado de control de la HTA mediante monitorización ambulatoria de la presión arterial. *Med Clin (Barc)*. 2001;116 Supl 2:114-21.
417. Márquez E, Casado JJ, Gil V, de la Figuera M, Martell N. Prevalencia del incumplimiento terapéutico en España entre los años 1984-2001. *Hipertensión*. 2002;19:12-6.
418. Márquez E, Casado JJ, Márquez JJ. Estrategias para mejorar el cumplimiento. *FMC*. 2001;8:558-73.
419. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. *Arch Intern Med*. 2004;164:722-32.
420. Smith SC, Blair N, Criqui MH, for the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. *J Am Coll Cardiol*. 1995;26:292-4.
421. Fernández C, Bardaji JL, Concha M, Cordo JC, Cosín J, Margina J, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en la angina estable. *Rev Esp Cardiol*. 2000;53:967-96.
422. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β -blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ*. 1999;318:1730-7.
423. The Danish Verapamil Infarction Trial II - DAVIT II. Effect of verapamil on mortality and major events after acute myocardial infarction. *Am J Cardiol*. 1990;66:779-85.
424. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. *N Engl J Med*. 1988;319:385-92.
425. Davis RC, Hobbs FD, Lip GYH. ABC of heart failure: history and epidemiology. *BMJ*. 2000;320:39-42.
426. Moser M, Herbert PR. Prevention of disease progression, left ventricular hypertrophy, and congestive heart failure in hypertension treatment trial. *J Am Coll Cardiol*. 1996;27:1214-8.
427. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. *Am J Hypertens*. 1992;5:95-110.
428. Schmieder R, Martus P, Klingbell A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. *JAMA*. 1996;275:1507-13.
429. Benjamin EJ, Levy D, Varizi SM. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. *JAMA*. 1994;271:840-4.
430. Madrid AH, Bueno MG, Rebollo JM, Marín I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. *Circulation*. 2002;106:331-6.
431. Madrid AH, Peng J, Zamora J, Marín I, Bernal E, Escobar C, et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. *Pacing Clin Electrophysiol*. 2004;27:1405-10.
432. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. *Arch Intern Med*. 2001;161:2125-8.
433. Black HR, Kuller LH, O'Rourke MF, Weber M, Alderman MH, Benetos A, et al. The first report of the Systolic and Pulse Pressure Working Group. *J Hypertens*. 1999;17 Suppl 5:S3-S14.

434. The INDANA Project Collaborators. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. *Stroke*. 1997;28:2557-62.
435. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Kidney Disease Outcome Quality Initiative*. *Am J Kidney Dis*. 2002;39 Suppl 1:S1-266.
436. Marín R, Gorostidi M. Nefroesclerosis. En: Hernando L, Aljama P, Arias M, Caramelo C, Egido J, Lamas S, editores. *Nefrología clínica*. Madrid: Editorial Médica Panamericana; 2003. p. 221-32.
437. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, for the HOPE Investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. *Ann Intern Med*. 2001;134:629-36.
438. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol*. 2004;15:1307-15.
439. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor to recurrent cardiovascular disease and mortality. *Am J Kidney Dis*. 2004;44:198-206.
440. Anavekar NS, McMurray JVV, Velázquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med*. 2004;351:1285-95.
441. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. *Am J Kidney Dis*. 2000;36:646-61.
442. Gorostidi M, Marín R. Tratamiento de la hipertensión arterial en enfermos con insuficiencia renal. Estadios 2 y 3 de la enfermedad renal crónica. *Nefrología*. 2004;24 Suppl 6:91-100.
443. Segura J. Bloqueo del sistema renina-angiotensina. *Nefrología*. 2004;24 Suppl 6:101-12.
444. Jacobson H. Ischemic renal disease. *Kidney Int*. 1988;34:729-43.
445. Alcázar JM, Rodicio JL. Ischemic nephropathy: clinical characteristics and treatment. *Am J Kidney Dis*. 2000;36:883-93.
446. McLaughlin K, Jardine AG, Moss JG. Renal artery stenosis. *BMJ*. 2000;320:1124-7.
447. Gorostidi M, Marín R. Nefropatía vascular. Concepto y significado. *Epidemiología. Hipertensión arterial esencial e insuficiencia renal. Nefrosclerosis. Nefropatía isquémica o aterosclerótica. Nefrología*. 2004;24 Suppl 6:73-83.
448. Marín R, Fernández-Vega F, Escalada P, Estevan JM, Barreiro A, Álvarez J. Factores de riesgo cardiovascular en la enfermedad arterial periférica. *Rev Clin Esp*. 1993;193:357-62.
449. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. *N Engl J Med*. 2001;344:1608-21.
450. Makin A, Lip GYH, Silverman S, Beevers DG. Peripheral vascular disease and hypertension: a forgotten association? *J Hum Hypertens*. 2001;15:447-54.
451. Black HR. The paradigm has shifted to systolic blood pressure. *Hypertension*. 1999;34:386-7.
452. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. *Arch Intern Med*. 1993;153:598-615.
453. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and generalizability of randomized trials. *JAMA*. 1994;272:1932-8.
454. Chaudhry SI, Krumhold HM, Foody JM. Systolic hypertension in older persons. *JAMA*. 2004;292:1074-80.
455. Black HR, Elliott WJ, Weber MA, Frishman WH, Strom JA, Liebson PR, et al, for the Stage 1 Systolic Hypertension (SISH) Study Group. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. *Hypertension*. 2001;28:1118-23.
456. Elliott WJ. Management of hypertension in the very elderly patient. *Hypertension*. 2004;44:800-4.
457. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekblom T, Fagard R, et al, for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. *Lancet*. 1999;353:793-96.
458. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremadura B, Nachev C, et al, on behalf of the Hypertensión in the Very Elderly Trial (HYVET) Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. *J Hypertens*. 2003;21:2409-17.
459. Beevers DG, Lip GYP. The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy. *J Hum Hypertens*. 2001;15:837-9.
460. Laakso M. Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study. *Circulation*. 1999;99:461-2.
461. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ, and the Collaborative Study Group. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. *Am J Kidney Dis*. 1999;34:809-17.
462. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. *N Engl J Med*. 2003;348:2285-93.
463. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. *Diabetes Care*. 2000;23:B54-64.
464. Asociación Española de Nefrología Pediátrica (AEN-PED), Sociedades Españolas de Diabetes (SEDIAB), Endocrinología y Nutrición (SEEN), Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEHLELHA), Medicina Familiar y Comunitaria (SEMFYC), Medicina Rural y Generalista (SEMERGEN) y Nefrología (SEN). Pautas de detección, prevención y tratamiento de la nefropatía diabética en España. *Hipertensión*. 2002;19:412-20.
465. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol*. 2000;183:S1-22.
466. Marín R, Portal CG, Gorostidi M, Sánchez M, Sánchez E, Fernández-Vega F, et al. Hipertensión arterial en el embarazo: estudio de 864 casos consecutivos observados durante un período de 24 años. *Nefrología*. 1999; 19: 308-17.
467. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomized placebo-controlled trial. *Lancet*. 2002;359:1877-90.
468. Roberts JS, Villar J, Avulkumarans S. Preventing and treating eclampsia seizures. *BMJ*. 2002;325:609-10.
469. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. *Lancet*. 2005;365:785-99.
470. Barth W. Low-dose aspirin for preeclampsia-the unresolved question. *N Engl J Med*. 1998;338:756-7.
471. Marín R, Gorostidi M, Portal CG, Sánchez M, Sánchez E, Álvarez J. Long-term prognosis of hypertension in pregnancy. *Hypertens Pregnancy*. 2000;19:199-209.
472. Rosenthal T, Oparil S. The effect of antihypertensive drugs on the fetus. *J Hum Hypertens*. 2002;16:293-8.
473. Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. *Hypertens Pregnancy*. 2002;21:85-95.
474. Baltar J, Marín R, Álvarez J. Toxicidad fetal de los fármacos antihipertensivos. *Hipertensión*. 2004;21:455-65.
475. Kaplan NM. Hypertension with pregnancy and the pill. En: Kaplan NM, editor. *Clinical hypertension*. Baltimore: Williams & Wilkins; 1998. p. 323-44.
476. Gabriel R, Labarthe DR, Forthofer R, Fernández-Cruz A, for the Spanish Group for the Study of Cardiovascular Risk Factors in Childhood and Youth. National standards for blood pressure for children and adolescents in

- Spain. International comparisons. *Int J Epidemiol.* 1992; 2:1-10.
477. Grupo Cooperativo Español para el Estudio de los Factores de Riesgo Cardiovascular en la Infancia y Adolescencia. Factores de riesgo cardiovascular en la infancia y adolescencia en España. Estudio RICARDIN II: principales valores de referencia. *An Esp Pediatr.* 1995;43:11-7.
478. Lieberman E. Hypertension in childhood and adolescence. En: Kaplan NM, editor. *Clinical Hypertension.* 7th ed. Baltimore: Williams & Wilkins; 1998. p. 407-20.
479. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery - executive summary. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Circulation.* 2002;105:1257-67.
480. Erstad BL, Barletta JF. Treatment of hypertension in the perioperative patient. *Ann Pharmacother.* 2000;34:66-79.
481. Tovar JL, Álvarez-Sabín J, Armario P, por el Comité de las Sociedades Catalanas de Hipertensión Arterial y de Neurología. Tratamiento del aumento de presión arterial en la fase aguda del ictus. Recomendaciones de las Sociedades Catalanas de Hipertensión Arterial y de Neurología. *Rev Neurol.* 1999;29:1271-6.
482. Van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. *Hypertension.* 2005;45:246-51.
483. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. *J Am Soc Nephrol.* 1998;9:133-42.
484. Alcázar JM. Uso y abuso del nifedipino sublingual. *Hipertensión.* 1997;14:87-8.
485. Gorostidi M, Baeza A, Jáuregui A, Marín R. Urgencias en hipertensión arterial. *Hipertensión.* 1999;16:90-9.
486. Vaughan CJ, Delanty N. Hypertensive emergencies. *Lancet.* 2000;356:411-7.
487. De la Figuera M, Arcas M, Vinyoles E. Tratamiento de las crisis hipertensivas. *FMC.* 2002;9:355-65.